Lillian Tseng

696 total citations
22 papers, 474 citations indexed

About

Lillian Tseng is a scholar working on Neurology, Surgery and Molecular Biology. According to data from OpenAlex, Lillian Tseng has authored 22 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Neurology, 7 papers in Surgery and 7 papers in Molecular Biology. Recurrent topics in Lillian Tseng's work include Neuroblastoma Research and Treatments (7 papers), Glioma Diagnosis and Treatment (5 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Lillian Tseng is often cited by papers focused on Neuroblastoma Research and Treatments (7 papers), Glioma Diagnosis and Treatment (5 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Lillian Tseng collaborates with scholars based in United States, United Kingdom and Canada. Lillian Tseng's co-authors include Mark W. Russo, Birgit Geoerger, Darren Hargrave, James A. Whitlock, Pooja Hingorani, Alberto Broniscer, Mark W. Kieran, Kohinoor Dasgupta, Éric Bouffet and Kenneth J. Cohen and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Lillian Tseng

21 papers receiving 473 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lillian Tseng United States 12 219 189 171 67 54 22 474
Hirotomo Tanaka Japan 13 198 0.9× 211 1.1× 184 1.1× 90 1.3× 50 0.9× 35 611
Jun Watanabe Japan 11 95 0.4× 160 0.8× 208 1.2× 72 1.1× 28 0.5× 35 478
Yufang Zhu China 13 79 0.4× 117 0.6× 162 0.9× 73 1.1× 70 1.3× 41 518
Meong Hi Son South Korea 14 159 0.7× 186 1.0× 220 1.3× 75 1.1× 48 0.9× 49 583
Nagaaki Katoh Japan 14 153 0.7× 80 0.4× 379 2.2× 106 1.6× 28 0.5× 61 647
Francesca Castiglione Italy 12 66 0.3× 115 0.6× 110 0.6× 125 1.9× 29 0.5× 40 445
Sami Khella United States 12 159 0.7× 41 0.2× 166 1.0× 41 0.6× 48 0.9× 29 461
Jingyi Fang China 16 148 0.7× 195 1.0× 75 0.4× 87 1.3× 39 0.7× 47 539
Samer E. Kaba United States 8 155 0.7× 84 0.4× 73 0.4× 61 0.9× 30 0.6× 11 414
Ivan Staikov Bulgaria 9 116 0.5× 99 0.5× 68 0.4× 132 2.0× 109 2.0× 19 508

Countries citing papers authored by Lillian Tseng

Since Specialization
Citations

This map shows the geographic impact of Lillian Tseng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lillian Tseng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lillian Tseng more than expected).

Fields of papers citing papers by Lillian Tseng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lillian Tseng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lillian Tseng. The network helps show where Lillian Tseng may publish in the future.

Co-authorship network of co-authors of Lillian Tseng

This figure shows the co-authorship network connecting the top 25 collaborators of Lillian Tseng. A scholar is included among the top collaborators of Lillian Tseng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lillian Tseng. Lillian Tseng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tseng, Lillian, et al.. (2024). Choriocarcinoma Syndrome: A Rare Complication's Impact on Metastatic Germ Cell Tumor Outcomes. Cureus. 16(4). e58388–e58388.
2.
Hargrave, Darren, Éric Bouffet, Uri Tabori, et al.. (2019). Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clinical Cancer Research. 25(24). 7303–7311. 125 indexed citations
3.
Kieran, Mark W., Birgit Geoerger, Ira J. Dunkel, et al.. (2019). A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors. Clinical Cancer Research. 25(24). 7294–7302. 58 indexed citations
4.
5.
Hargrave, Darren, Lucas Moreno, Alberto Broniscer, et al.. (2018). Dabrafenib in pediatric patients with BRAF V600–positive high-grade glioma (HGG).. Journal of Clinical Oncology. 36(15_suppl). 10505–10505. 6 indexed citations
6.
Geoerger, Birgit, Christopher L. Moertel, James A. Whitlock, et al.. (2018). Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).. Journal of Clinical Oncology. 36(15_suppl). 10537–10537. 18 indexed citations
7.
Bouffet, Éric, Mark W. Kieran, Darren Hargrave, et al.. (2018). LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB. Neuro-Oncology. 20(suppl_2). i114–i114. 22 indexed citations
8.
Kieran, Mark W., Éric Bouffet, Alberto Broniscer, et al.. (2018). Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed refractory low-grade glioma.. Journal of Clinical Oncology. 36(15_suppl). 10506–10506. 14 indexed citations
9.
Kieran, Mark W., Éric Bouffet, Uri Tabori, et al.. (2016). CNS tumours The first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas. Annals of Oncology. 27. vi557–vi557. 13 indexed citations
10.
11.
12.
13.
Schnitzer, Thomas J., B. Seriolo, Hartmut Schneider, et al.. (2011). A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis. Clinical Rheumatology. 30(11). 1433–1446. 11 indexed citations
14.
Choueiri, Toni K., Sumanta K. Pal, Maria E. Cabanillas, et al.. (2011). Antitumor activity observed in a phase I drug–drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC).. Journal of Clinical Oncology. 29(15_suppl). e13042–e13042. 7 indexed citations
15.
Vergote, I., Avishay Sella, Cindi Bedell, et al.. (2010). 407 Phase 2 study of XL184 in a cohort of ovarian cancer patients (pts) with measurable soft tissue disease. European Journal of Cancer Supplements. 8(7). 129–129. 3 indexed citations
16.
Brenner, Matthew, Sari Mahon, Lillian Tseng, et al.. (2008). In vivo optical coherence tomography detection of differences in regional large airway smoke inhalation induced injury in a rabbit model. Journal of Biomedical Optics. 13(3). 34001–34001. 22 indexed citations
17.
El-Abbadi, Naglaa, et al.. (2008). Development of a rabbit pleural cancer model by using VX2 tumors.. PubMed. 58(3). 287–93. 7 indexed citations
18.
Brenner, Matthew, David Mukai, Shuguang Guo, et al.. (2007). Detection of acute smoke-induced airway injury in a New Zealand white rabbit model using optical coherence tomography. Journal of Biomedical Optics. 12(5). 51701–51701. 14 indexed citations
19.
Tseng, Lillian, et al.. (2005). Lumiracoxib Is Effective in the Treatment of Episodic Tension‐Type Headache. Headache The Journal of Head and Face Pain. 45(9). 1163–1170. 6 indexed citations
20.
Salles, Antonio A. F. De, Leonardo Frighetto, Shantanu Sinha, et al.. (2004). Functional Neurosurgery in the MRI Environment. min - Minimally Invasive Neurosurgery. 47(5). 284–289. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hirotomo Tanaka Breakdown of academic impact, for papers by Jun Watanabe Breakdown of academic impact, for papers by Yufang Zhu Breakdown of academic impact, for papers by Meong Hi Son Breakdown of academic impact, for papers by Nagaaki Katoh Breakdown of academic impact, for papers by Francesca Castiglione Breakdown of academic impact, for papers by Sami Khella Breakdown of academic impact, for papers by Jingyi Fang Breakdown of academic impact, for papers by Samer E. Kaba Breakdown of academic impact, for papers by Ivan Staikov
Rankless by CCL
2026